Literature DB >> 33987775

An Update on the State of Tau Radiotracer Development: a Brief Review.

Grant Rigney1, Cyrus Ayubcha2, Thomas J Werner3, Abass Alavi4.   

Abstract

Evolving scientific evidence has begun to point towards hyperphosphorylated tau as a major neurotoxic component in the pathophysiological development of many major neurodegenerative conditions. In response to a need for accurate and reliable diagnosis and disease monitoring in clinical and trial settings, there has been great effort put into the development of tau radiotracers. While first-generation and second-generation radiotracers have provided a basis for assessing tau, concerns of inadequate specificity and selectivity have continued to motivate further study of these radiotracers and the development of novel radiopharmaceuticals. Given the prospective scientific and clinical value of a valid tau radiotracer, the molecular neuroimaging community must be aware of the most recent developments in the realm of tau radiotracer development. This brief review article will critically overview the most established tau radiotracers and, most importantly, concentrate on the progress of more recently developed tau radiotracers.
© 2021. World Molecular Imaging Society.

Entities:  

Keywords:  First generation; Neurodegeneration; Neuroimaging; PET; Radiotracers; Second generation; Tau

Mesh:

Substances:

Year:  2021        PMID: 33987775     DOI: 10.1007/s11307-021-01612-1

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  14 in total

1.  In vivo characterization of chronic traumatic encephalopathy using [F-18]FDDNP PET brain imaging.

Authors:  Jorge R Barrio; Gary W Small; Koon-Pong Wong; Sung-Cheng Huang; Jie Liu; David A Merrill; Christopher C Giza; Robert P Fitzsimmons; Bennet Omalu; Julian Bailes; Vladimir Kepe
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

2.  Is Tau Imaging More Than Just Upside-Down 18F-FDG Imaging?

Authors:  Thilo van Eimeren; Gérard N Bischof; Alexander Drzezga
Journal:  J Nucl Med       Date:  2017-05-10       Impact factor: 10.057

3.  Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.

Authors:  Rik Ossenkoppele; Nelleke Tolboom; Jessica C Foster-Dingley; Sofie F Adriaanse; Ronald Boellaard; Maqsood Yaqub; Albert D Windhorst; Frederik Barkhof; Adriaan A Lammertsma; Philip Scheltens; Wiesje M van der Flier; Bart N M van Berckel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-23       Impact factor: 9.236

Review 4.  A critical review of radiotracers in the positron emission tomography imaging of traumatic brain injury: FDG, tau, and amyloid imaging in mild traumatic brain injury and chronic traumatic encephalopathy.

Authors:  Cyrus Ayubcha; Mona-Elisabeth Revheim; Andrew Newberg; Mateen Moghbel; Chaitanya Rojulpote; Thomas J Werner; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-07-21       Impact factor: 9.236

5.  Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease.

Authors:  Sergey Shcherbinin; Adam J Schwarz; Abhinay Joshi; Michael Navitsky; Matthew Flitter; William R Shankle; Michael D Devous; Mark A Mintun
Journal:  J Nucl Med       Date:  2016-05-05       Impact factor: 10.057

6.  Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology.

Authors:  My Jonasson; Anders Wall; Konstantinos Chiotis; Laure Saint-Aubert; Helena Wilking; Margareta Sprycha; Beatrice Borg; Alf Thibblin; Jonas Eriksson; Jens Sörensen; Gunnar Antoni; Agneta Nordberg; Mark Lubberink
Journal:  J Nucl Med       Date:  2016-01-21       Impact factor: 10.057

Review 7.  Tau and neurodegenerative disease: the story so far.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong
Journal:  Nat Rev Neurol       Date:  2015-12-04       Impact factor: 42.937

8.  18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease.

Authors:  Ryuichi Harada; Nobuyuki Okamura; Shozo Furumoto; Katsutoshi Furukawa; Aiko Ishiki; Naoki Tomita; Tetsuro Tago; Kotaro Hiraoka; Shoichi Watanuki; Miho Shidahara; Masayasu Miyake; Yoichi Ishikawa; Rin Matsuda; Akie Inami; Takeo Yoshikawa; Yoshihito Funaki; Ren Iwata; Manabu Tashiro; Kazuhiko Yanai; Hiroyuki Arai; Yukitsuka Kudo
Journal:  J Nucl Med       Date:  2015-11-05       Impact factor: 10.057

Review 9.  Tau PET imaging in neurodegenerative tauopathies-still a challenge.

Authors:  Antoine Leuzy; Konstantinos Chiotis; Laetitia Lemoine; Per-Göran Gillberg; Ove Almkvist; Elena Rodriguez-Vieitez; Agneta Nordberg
Journal:  Mol Psychiatry       Date:  2019-01-11       Impact factor: 15.992

10.  18F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty.

Authors:  Jung-Lung Hsu; Shih-Hsin Chen; Ing-Tsung Hsiao; Chin-Song Lu; Tzu-Chen Yen; Nobuyuki Okamura; Kun-Ju Lin; Yi-Hsin Weng
Journal:  Sci Rep       Date:  2020-11-10       Impact factor: 4.379

View more
  1 in total

1.  Tau-PET imaging as a molecular modality for Alzheimer's disease.

Authors:  Cyrus Ayubcha; Grant Rigney; Austin J Borja; Thomas Werner; Abass Alavi
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-10-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.